Patents

Update of patent trial on antithrombotic drug reported

Published in Blood Weekly, July 14th, 2005

On June 15, 2005, the U.S. District Court for the Central District of California granted the motion for summary judgment for inequitable conduct filed by Amphastar Pharmaceuticals, Inc. in the sanofi-aventis Group's suit against Amphastar and Teva Pharmaceuticals USA, Inc. for infringement of U.S. Patent no. 5,389,618 by their proposed generic versions of Lovenox.

A formal entry of this ruling as a final judgment of the court would result in the lifting of the 30-month stay on U.S. Food and Drug Administration (FDA) approval, which has been in place since the initiation of this patent infringement suit. While Amphastar and Teva have requested marketing approval from the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2005-07-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry